Oscar Health (OSCR) is back in focus after management used the Goldman Sachs Healthcare Conference to reaffirm full year 2026 guidance, highlight healthier than expected market morbidity, and point to membership trends that support its current outlook.

At a share price of $28.91, Oscar Health has seen very strong momentum recently, with a 22.5% 7 day share price return and a 93.1% year to date share price return. The 1 year total shareholder return of 101.6% and 3 year total shareholder return of just over 3x underline how recent conference commentary, margin trends and the Barclays upgrade are being reflected in both short and longer term performance.

If you are interested in how AI is reshaping healthcare beyond Oscar Health, this is a useful moment to scan the market using the 40 healthcare AI stocks.

After a surge that has pushed Oscar Health to fresh highs and above some published price targets, investors now face a simple question: is there still mispricing to work with here, or is the market already baking in future growth?

Most Popular Narrative: 88% Overvalued

At a last close of $28.91 against a most-followed fair value of $15.40, the prevailing narrative frames Oscar Health as already pricing in a lot of the expected earnings power, with a relatively modest discount rate of 6.98% used to bring those forecasts back to today.

The analysts have a consensus price target of $15.4 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of just $10.0.

Curious what kind of revenue ramp, margin swing and profit profile sit behind that fair value and discount rate? The narrative leans on a sharp earnings turnaround, faster top line expansion than the market and a future profitability level that reshapes how this stock could be valued.

Result: Fair Value of $15.40 (OVERVALUED)

However, there are still real swing factors here, including higher claims costs in the ACA market and policy changes that could shrink Oscar Health's addressable member base.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: What The Market Multiple Is Saying

While the most followed fair value points to Oscar Health as 88% overvalued at $15.40 versus a $28.91 share price, the current P/S ratio of 0.7x tells a different story. It sits below peers at 1.2x and is in line with a fair ratio of 0.7x. This suggests the market may not be overpaying for each dollar of revenue in the same way the narrative implies.

For you, that gap between a seemingly stretched narrative value and a relatively modest sales multiple raises a simple question. Is the real risk that expectations are too high, or that the stock is being judged on the wrong yardstick for now?

Next Steps

With sentiment clearly split between rich valuation signals and more neutral revenue multiples, this is a moment to move quickly and stress test the full picture for yourself. To weigh both sides, start by checking the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with Oscar Health, you only see part of the opportunity set. Broaden your watchlist now so you are not late to the next move.

• Spot potential mispricing quickly by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Focus on stability first and check 67 resilient stocks with low risk scores built around companies with more resilient risk profiles.
• Hunt for future standouts early with the screener containing 20 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.